Search results
Viatris is a global pharmaceutical company that believes in healthcare not as it is, but as it should be. Learn about our story, explore our products and browse career opportunities.
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020. [2]
Viatris is a unique global healthcare company focused on a wide variety of therapeutic areas, empowering people worldwide by expanding their access to a broad range of trusted, quality medications, regardless of geography or circumstance.
With one of our global centers located in Hyderabad, we have a strong presence in India, where our development and manufacturing facilities support the production of high-quality medicines for global markets.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically...
Nov 12, 2019 · Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIA”—to three—“TRIS”—core goals: expanding access to medicines, leading by innovating to meet patient needs, and being a trusted partner for the healthcare community worldwide.
The Investor Relations website contains information about Viatris's business for stockholders, potential investors, and financial analysts.
Mylan is now part of Viatris, a new global healthcare company committed to empowering people to live healthier at every stage of life. We encourage you to learn more about our commitment to increasing access to quality medicines for patients when and where they need them. Explore Viatris.
Find the latest Viatris Inc. (VTRS) stock quote, history, news and other vital information to help you with your stock trading and investing.
Jun 3, 2024 · Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that the European Commission (EC) has approved the planned divestiture of substantially all of Viatris’ Over-the-Counter (OTC) business to Cooper Consumer Health (CCH).
